Mastrogiacomo M, Cancedda R, Quarto R
Centro di Biotecnologie Avanzate/Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Osteoarthritis Cartilage. 2001;9 Suppl A:S36-40. doi: 10.1053/joca.2001.0442.
The aim of this study was to investigate the effects of different growth factors on the chondrogenic potential of human bone marrow stromal cells (BMSC).
Different growth factors which have been shown to sustain the osteogenic potential of BMSC during their 'in vitro' expansion were assayed for the maintenance of the chondrogenic potential. We compared the ability of BMSC to reconstitute cartilage in vitro with their ability to form bone on hydroxyapatite microporous particles in an ectopic bone formation assay.
Among the factors assayed, fibroblast growth factor 2 (FGF2) was the most effective in promoting growth of BMSC 'in vitro'. For all growth factors tested, we have found a complete overlap of the enhancement of chondrogenic and osteogenic potential. Any factor, either promoting or depressing bone formation, exerted the same effect on the chondrogenic potential of human BMSC. In particular, FGF2, either alone or in combination with other factors, strongly supported the formation of bone as well as of cartilage.
We conclude that FGF2 maintains human BMSC in an immature state allowing their 'in vitro' expansion. Expanded cells retain the chondro- osteogenic potential. Interestingly, the chondrogenic potential of BMSC 'in vitro' is directly related to their ability to form bone 'in vivo'. BMSC expanded 'ex vivo' are presently being proposed for cell therapy of bone defects. 'In vitro' chondrogenesis may be regarded as a rapid prediction assay to assess cell ability to form bone after 'in vivo' transplant.
本研究旨在探讨不同生长因子对人骨髓基质细胞（BMSC）软骨形成潜能的影响。
检测了不同生长因子在BMSC“体外”扩增过程中维持其成骨潜能的情况，以评估它们对软骨形成潜能的维持作用。我们在异位骨形成试验中比较了BMSC在体外重建软骨的能力与其在羟基磷灰石微孔颗粒上形成骨的能力。
在所检测的因子中，成纤维细胞生长因子2（FGF2）在促进BMSC“体外”生长方面最为有效。对于所有测试的生长因子，我们发现软骨形成潜能增强与成骨潜能增强完全重叠。任何促进或抑制骨形成的因子对人BMSC的软骨形成潜能都有相同的作用。特别是，FGF2单独或与其他因子联合使用时，都能强烈支持骨和软骨的形成。
我们得出结论，FGF2使人类BMSC维持在未成熟状态，使其能够“体外”扩增。扩增后的细胞保留了软骨-成骨潜能。有趣的是，BMSC“体外”的软骨形成潜能与其“体内”形成骨的能力直接相关。目前正在提议将“体外”扩增的BMSC用于骨缺损的细胞治疗。“体外”软骨形成可被视为一种快速预测试验，以评估细胞在“体内”移植后形成骨的能力。
